Market Place
Sourcing Support
Design Therapeutics to Join Jefferies Global Health Conference
28 May 2025 //
GLOBENEWSWIRE
Design Therapeutics to Join 2025 RBC Capital Markets Conference
13 May 2025 //
GLOBENEWSWIRE
Design Therapeutics Highlights Lead GeneTAC Programs and Q1 2025
07 May 2025 //
GLOBENEWSWIRE
Design Therapeutics Reports Positive Phase 1 Data for DT-168
01 May 2025 //
GLOBENEWSWIRE
Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial
21 Apr 2025 //
GLOBENEWSWIRE
Design Therapeutics Names Chris Storgard, CMO
17 Apr 2025 //
GLOBENEWSWIRE
Design Highlights GeneTAC Progress, Reports Q4, Full-Year 2024
10 Mar 2025 //
GLOBENEWSWIRE
Design To Join Leerink’s Global Healthcare Conference
03 Mar 2025 //
GLOBENEWSWIRE
Design Therapeutics to Attend Multiple Investor Conferences
13 Nov 2024 //
GLOBENEWSWIRE
Design Therapeutics Q3 2024 Results & GeneTACTM Milestones
07 Nov 2024 //
GLOBENEWSWIRE
Design Therapeutics To Attend Cantor Healthcare Conference
10 Sep 2024 //
GLOBENEWSWIRE
Design Therapeutics Reports Q2 2024 Results And GeneTAC™ Milestones
05 Aug 2024 //
GLOBENEWSWIRE
Design Therapeutics Q1 2024 Results, Program Milestones
08 May 2024 //
GLOBENEWSWIRE
Design Therapeutics At RBC Healthcare Conference
07 May 2024 //
GLOBENEWSWIRE
Design Outlines Progress Across GeneTAC„ Platform & Announces4Q FYR 2023
19 Mar 2024 //
GLOBENEWSWIRE
Design Therapeutics to Webcast Fourth Quarter & Full Year 2023 Financial Results
12 Mar 2024 //
GLOBENEWSWIRE
Design Therapeutics hints at ‘strategic realignment,’ replaces CEO
17 Nov 2023 //
ENDPTS
Design Therapeutics Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
Design Therapeutics to reformulate Friedreich`s ataxia drug,delay trial timeline
15 Aug 2023 //
ENDPTS
Design rethinks lead drug, causing delay and steep stock drop
15 Aug 2023 //
FIERCE BIOTECH
Design Reports Initial Results from Phase 1 Study of DT-216
14 Aug 2023 //
GLOBENEWSWIRE
Design Therapeutics Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference
31 May 2023 //
GLOBENEWSWIRE
Design Therapeutics Provides Pipeline Updates and Reports1Q 2023 FYR
09 May 2023 //
GLOBENEWSWIRE
Design Therapeutics to Present Data on its GeneTAC Small Molecule, DT-168
24 Apr 2023 //
GLOBENEWSWIRE
Design Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
14 Mar 2023 //
GLOBENEWSWIRE
Design Therapeutics to Participate in the SVB Securities Biopharma Conference
08 Feb 2023 //
GLOBENEWSWIRE
Design Therapeutics Reports +ve Data from Single-Ascending Dose Trial of DT-216
07 Dec 2022 //
GLOBENEWSWIRE
Design Highlights Pipeline Progress and Upcoming Milestones and Reports 3Q FYR
03 Nov 2022 //
GLOBENEWSWIRE
Design to Present Preclinical Data Highlighting the Potential of its GeneTAC™
17 Oct 2022 //
GLOBENEWSWIRE
Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic
22 Sep 2022 //
GLOBENEWSWIRE
Design Tx Highlights Upcoming Milestones and Reports Q2 2022 Financial Results
08 Aug 2022 //
GLOBENEWSWIRE
Design Tx to Participate in the 2022 Wedbush Virtual Healthcare Conference
03 Aug 2022 //
GLOBENEWSWIRE
Design Therapeutics to Present at the 2022 Jefferies Healthcare Conference
01 Jun 2022 //
GLOBENEWSWIRE
Design Therapeutics Reports First Quarter 2022 Financial Results
09 May 2022 //
GLOBENEWSWIRE
Design Tx Completes Dosing in First Patient Cohort of Phase 1 Trial of DT-216
30 Mar 2022 //
GLOBENEWSWIRE
Design Tx Reports Q4 and FY 2021 Financial Results
10 Mar 2022 //
GLOBENEWSWIRE
Design Tx says PC Data Highlighting Novel GeneTAC Therapy at AVRO
09 Mar 2022 //
GLOBENEWSWIRE
FDA Clears Design Tx`s IND for First GeneTAC Molecule for Friedreich Ataxia
28 Feb 2022 //
GLOBENEWSWIRE
Design Therapeutics to Present at the SVB Leerink 11th Annual Conference
10 Feb 2022 //
GLOBENEWSWIRE
Design Therapeutics Announces Positive Preclinical Data for DM1 GeneTACs in DM1
08 Sep 2021 //
GLOBENEWSWIRE
Design Therapeutics Announces Pricing of Initial Public Offering
26 Mar 2021 //
GLOBENEWSWIRE
Preclinical genetic disease biotech Design Therapeutics sets terms for $228M IPO
22 Mar 2021 //
NASDAQ
